AKT1 and gastric cancer: Shen J et al. (2023) found that baicalein (30, 60, 120 μM for 48 h) dose-dependently upregulated the expression of GRP78 and CHOP and blocked the PI3K/AKT pathway to trigger the ERS, blocking the cell cycle at G0/G1 phase and inhibited the proliferation of GC HGC-27 and AGS cells. The above effects were reversed with the addition of ERS inhibitor 4-PBA. In vivo experiments also confirmed that GC progression was significantly prevented in AGS subcutaneous xenograft mice treated with baicalein (15, 50 mg/kg/d for 4 weeks).